Agilon Health Reports Q3 2026 Results, Raises Full-Year Guidance
Revenue was $1.52 billion, up 6% year over year; net income was $35 million and Adjusted EBITDA was $64 million. The company raised its 2026 revenue outlook to $5.87 billion-$5.89 billion and Adjusted EBITDA outlook to $145 million-$155 million.
For the third quarter ended September 30, 2026, agilon health reported revenue of $1.52 billion, a 6% increase year-over-year, which surpassed consensus estimates. The company achieved net income of $35 million, compared to a net loss in the same period last year, and reported Adjusted EBITDA of $64 million. The medical services expense ratio improved to 88.5% from 104.0% in the prior-year quarter. Following these results, the company raised its full-year 2026 guidance, now projecting revenue between $5.87 billion and $5.89 billion and Adjusted EBITDA between $145 million and $155 million.
Management attributed the performance to disciplined execution and operational progress, noting that membership changes reflected a focus on profitability and market exits.